IPHA
Innate Pharma·NASDAQ
--
--(--)
--
--(--)
6.53 / 10
Outperform
The firm exhibits satisfactory fundamental strength scoring 6.5/10. Supportive aspects: Fixed assets turnover ratio and Inventory turnover ratio, offset by weaknesses in Current assets turnover ratio. Investment verdict: positive.
Analysis Checks(3/4)
Inventory turnover ratio
Value38.02
Score2/3
Weight586.08%
1M Return-2.37%
Value38.02
Score2/3
Weight586.08%
1M Return-2.37%
Current assets turnover ratio
Value0.06
Score1/3
Weight-70.89%
1M Return0.27%
Value0.06
Score1/3
Weight-70.89%
1M Return0.27%
Gross profit margin (%)
Value100.00
Score2/3
Weight-406.96%
1M Return1.40%
Value100.00
Score2/3
Weight-406.96%
1M Return1.40%
Fixed assets turnover ratio
Value0.96
Score2/3
Weight-8.23%
1M Return0.03%
Value0.96
Score2/3
Weight-8.23%
1M Return0.03%
Inventory turnover ratio
Value38.02
Score2/3
Weight586.08%
1M Return-2.37%
Value38.02
Score2/3
Weight586.08%
1M Return-2.37%
Gross profit margin (%)
Value100.00
Score2/3
Weight-406.96%
1M Return1.40%
Value100.00
Score2/3
Weight-406.96%
1M Return1.40%
Current assets turnover ratio
Value0.06
Score1/3
Weight-70.89%
1M Return0.27%
Value0.06
Score1/3
Weight-70.89%
1M Return0.27%
Fixed assets turnover ratio
Value0.96
Score2/3
Weight-8.23%
1M Return0.03%
Value0.96
Score2/3
Weight-8.23%
1M Return0.03%
Is IPHA undervalued or overvalued?
- IPHA scores 6.53/10 on fundamentals and holds a Discounted valuation at present. Backed by its -305.39% ROE, -373.78% net margin, -3.22 P/E ratio, 26.47 P/B ratio, and -30.92% earnings growth, these metrics solidify its Outperform investment rating.
